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Introduction
The characterisation of the molecular mechanism of dis-
ease allows classification of patients into subtypes and
potentially identifies specific targets for therapeutic inter-
vention. Tyrosine kinase mutations are central to specific
targeted therapy. Investigation of kinase deregulation
within particular patient groups, has led to identification
of mutant tyrosine kinases associated with disease progres-
sion and therapy modulation. Biomarker-specific therapies
emerged, taking a leading role in guided-therapy. The
extensive use of the specific kinase inhibitors and the long-
evity of the treatment protocols due to the uncertainty of
residual disease, gave rise to new challenges, namely sec-
ondary resistance to therapy. Although there are various
mechanisms of acquired resistance, mutations in the drug
target itself play a dominant role.
Scientific objectives
Our previous studies using cellular models show the
importance of suppressed feedback mechanisms, in parti-
cular the regulation of the phosphatase, pp2a. Following
extensive molecular classification of patients, the aim of
this study was to identify variants and transcript isoforms
of PPP2CA and its inhibiting subunits ALPHA4 and SET,
using (1) cell lines derived from haematopoietic disease,
and (2) Chronic Myeloid Leukemia (CML) and Acute
Myeloid Leukemia (AML) patient material.
Technological approaches
Patients were classified according to molecular defects
using well established protocols. The expression of
phosphatase regulators was measured using Real Time
PCR. The catalytic subunit, PPP2CA was screened for
variation at the level of mutations and isoforms using
High Resolution Melting analysis. cDNA was utilised for
this screen. Variants were further characterised by
sequencing.
Results interpretation
A preliminary analysis investigating the co-occurrence of
FLT3 and Core Binding Factor (CBF) mutations charac-
terised these mutations simultaneously in some patients.
This indicates an interaction between these two distinct
classes of mutations, in addition to the well known asso-
ciation of KIT mutants in CBF patients. The presence of
KIT mutations predicts the use of the Tyrosine Kinase
Inhibitor, Imatinib. Following classifications using
known mutations in kinases and transcription factors,
the variation in the tumour suppressor, pp2a was inves-
tigated. Variation in the PPP2CA transcript is minimal
and the identified nucleotide changes were synonymous.
HRM identified mutants in SET and alpha4. Of interest
the cell line, U937 has multiple mutations in the coding
region of SET. PPP2CA isoforms were identified in
patient material. One of the isoforms, is predominantly
expressed in 15% of CML (n=19) and AML (n=344)
patients. In addition, the characterisation of a novel
PPP2CA isoform in the BCR/ABL positive cell line
BV173 indicates that such isoforms may be associated
with progression of disease and potentially chemo-
resistance.
Outlook and expert recommendations
Loss-of-function mutations in the phosphatase, pp2a
and/or an enhanced pp2a inhibition due to increased
expression of pp2a regulators (such as CIP2A, SETBP1)
* Correspondence: godfrey.grech@um.edu.mt
† Contributed equally
1Department of Pathology, University of Malta, Malta, Italy
Full list of author information is available at the end of the article
Grech et al. EPMA Journal 2014, 5(Suppl 1):A26
http://www.epmajournal.com/content/5/S1/A26
© 2014 Grech et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
will provide a new classification of patients in various
malignancies. Of interest, these subtypes will provide
the basis to investigate the use of pp2a activators as
therapeutic drugs.
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